Skip to main content
Start triage

Start triage first, then route to emergency care.

Need urgent help? Start triage first, then route to emergency care.

Roxee Meds Catalog

Insulin Injectable Vial

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Both Catalog complete FDA data linked Rx required Liquid (Suspension) Boehringer Ingelheim Animal Health USA, Inc. Official label facts Owner quick guide first

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts
Catalog refreshed
Apr 22, 2026, 10:13 a.m.

These are the storefront facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
May 5, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
May 5, 2026, 10:01 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Storefront facts: Source Roxee | Refreshed Apr 22, 2026, 10:13 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: April 22, 2026

Updated: April 22, 2026, 10:13 AM UTC

Sources:
Image coming soon
Insulin Injectable Vial

Insulin Injectable Vial

Drug type: Generic ingredient • Generic profile No FDA branded products linked

Both Liquid (Suspension) Rx required 100% storefront ready

Species: Both

Manufacturer: Boehringer Ingelheim Animal Health USA, Inc.

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Insulin Injectable Vial

For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in cats with diabetes mellitus. For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabetes mellitus. Species commonly shown: Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied.

Generic name
Insulin Injectable Vial
Brand names
ProZinc®
Manufacturer
Boehringer Ingelheim Animal Health USA, Inc.
Species
Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied
Dosage forms
Liquid (Suspension)
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
ProZinc®
Dosage forms
Liquid (Suspension)

Indications / Uses

For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in cats with diabetes mellitus. For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabetes mellitus.

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use of a syringe other than a U-40 syringe will result in incorrect dosing. For subcutaneous injection in cats only.

  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use of a syringe other than a U-40 syringe will result in incorrect dosing. For subcutaneous injection in cats only.

Side Effects

Top reported reactions (openFDA): INEFFECTIVE, GLYCEMIC CONTROL, Lack of efficacy - NOS, Hypoglycaemia, INEFFECTIVE, LOSS OF EFFECT, Wrong technique in drug usage process, Lethargy (see also Central nervous system depression in 'Neurological').

FAQ

Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied

Yes. Roxee shows this as prescription-only.

Liquid (Suspension)

Source Transparency

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in cats with diabetes mellitus.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Use of a syringe other than a U-40 syringe will result in incorrect dosing
  • For subcutaneous injection in cats only
  • Loss of appetite (1 reports)
  • Elevated cholesterol (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

Bloodwork changes are grouped in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Major cautions & emergency warning signs

Side effects to monitor:

  • Use of a syringe other than a U-40 syringe will result in incorrect dosing
  • For subcutaneous injection in cats only
  • Loss of appetite
  • Elevated cholesterol

Most reported reactions:

  • Loss of appetite (1 reports)
  • Elevated creatinine (1 reports)
  • Elevated cholesterol (1 reports)

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Boehringer Ingelheim Animal Health USA, Inc.
Form: Liquid (Suspension)
Identifiers:
NADA: 141297
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use of a syringe other than a U-40 syringe will result in incorrect dosing. For subcutaneous injection in cats only.

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use of a syringe other than a U-40 syringe will result in incorrect dosing. For subcutaneous injection in cats only.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
28
Species represented
2
Grouped by Body System
Digestive (4) · Loss of appetite, Diarrhea, Decreased appetite Neurologic (1) · Unsteady walking (ataxia) Behavior (1) · Behavioral disorder (unspecified) Other (26) · Elevated creatinine, Elevated cholesterol, Elevated blood urea nitrogen
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Digestive 1 Cat 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Digestive 1 Cat 1

Species coverage: Cat (22) Dog (10)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Dog Non-serious - 1
Digestive Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Digestive Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Digestive Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Behavior Cat Serious - 1
Other Cat Serious - 1
Digestive Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

2

SPL

1

FOI

2

Final Version PROZINC N141297.pdf

Official label / PI · Labeling

Final Version PROZINC N141297.pdf

Official label / PI · Labeling

ProZinc®

SPL · SPL

FDA Structured Product Label

ProZinc®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Boehringer Ingelheim Animal Health USA, Inc.
NADA
141-297
Status
RX
Form
Liquid (Suspension)
Route
Subcutaneous
Species
Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each mL contains 40 international units (IU) insulin.

Cats

Indication
For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in cats with diabetes mellitus.
Dosage
The initial recommended dose is 0.1 to 0.3 IU insulin/pound of body weight (0.2 to 0.7 IU/kg) every 12 hours. The dose should be given concurrently with or right after a meal.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use of a syringe other than a U-40 syringe will result in incorrect dosing. For subcutaneous injection in cats only.

Dogs

Indication

For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabetes mellitus.

Dosage

Starting dose: The recommended starting dose for ProZinc® is 0.2-0.5 IU insulin/pound of body weight (0.5-1.0 IU/kg) once daily. The recommended starting dose for naïve dogs is the lower end of the dose range. The recommended starting dose for dogs with poorly controlled diabetes mellitus and transitioning from another insulin product is the mid to higher end of the dose range based on the veterinarian’s experience with the dog’s medical history and previous insulin dose. When transitioning from another insulin, the dog’s blood glucose and general condition should be closely monitored. When transitioning from another insulin, ProZinc® should be started once daily regardless of the frequency of prior insulin use.

The dose should be given concurrently with or right after a meal. The veterinarian should re-evaluate the dog at appropriate intervals and adjust the dose and frequency based on both clinical signs and laboratory test results (the blood glucose curve values and shape, nadir, and fructosamine) until adequate glycemic control has been attained. In the effectiveness field study, glycemic control was considered adequate if the glucose nadir from a 9-hour blood glucose curve was between 80 and 125 mg/dL, the maximum blood glucose was lessThanEqualTo 300 mg/dL, and clinical signs of hyperglycemia such as polyuria, polydipsia, or weight loss were improved.

Changing to twice daily dosing: Twice daily dosing should be considered if the duration of insulin action is determined to be inadequate with once daily dosing. Use caution when adjusting from once daily to twice daily dosing because ProZinc® may have prolonged duration of action in some dogs. The veterinarian should closely monitor the duration of action using blood glucose curves to avoid the increased risk of hypoglycemia. If twice daily dosing is initiated, the two doses should each be approximately 25% less than the once daily dose required to attain an acceptable glucose nadir. For example, if a dog receiving 10 units of ProZinc® once daily has an acceptable nadir but inadequate duration of activity, the dose should be changed to 7 units twice daily (round down to the nearest whole unit).

Further adjustments in the dosage may be necessary with changes in the dog’s diet, body weight, or concomitant medication, or if the dog develops concurrent infection, inflammation, neoplasia, or an additional endocrine or other medical disorder.

FOI Summary sN 141-297 Approved February 8, 2019.pdf

FOI · FOI

UCM198121.pdf

FOI · FOI

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Storefront facts: Source Roxee | Refreshed Apr 22, 2026, 10:13 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Official (FDA)
Identity: Generic ingredient • No FDA branded products linked
No official FDA brand rows linked yet for this ingredient.
Case-reported brands (openFDA): MSK
Catalog species: Both FDA-labeled species: Cat, Dog
Rx/OTC: RX
Form/route: Liquid (Suspension) Subcutaneous
Applications: NADA 141-297
Documents: 4 (FOI: 2) • SPL: 1 Label highlights Official documents
Safety (openFDA)
Top reactions: Dog 20 Cat 36 View
Case summaries: 11 (showing 8) View
openFDA reports are unverified and do not prove causation.

Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes
ICD10_CM: E11.9
Type 2 diabetes mellitus without complications

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use of a syringe other than a U-40 syringe will result in incorrect dosing. For subcutaneous injection in cats only. (Contraindication, High)
Top reaction signals
Loss of appetite (1) Elevated creatinine (1) Elevated cholesterol (1) Elevated alanine aminotransferase (1) Distress (1) Digestive tract disorder NOS (1) Difficulty in micturition (1) Diarrhea (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141297

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 18 Clinical 2 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): INEFFECTIVE, GLYCEMIC CONTROL, Lack of efficacy - NOS, Hypoglycaemia, INEFFECTIVE, LOSS OF EFFECT, Wrong technique in drug us… (Clinical, 2026-04-15)
  • side_effects: Top reported reactions (openFDA): INEFFECTIVE, GLYCEMIC CONTROL, Lack of efficacy - NOS, Hypoglycaemia, INEFFECTIVE, LOSS OF EFFECT, Wrong technique in drug us… (Clinical, 2026-04-11)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use of a syringe other than a U-40 syringe will result in incorrect dosin… (Official, 2026-04-22)
  • indications: This supplement provides for the addition of the indication for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabete… (Official, 2026-05-05)
  • indications: This supplement provides for the addition of the indication for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabete… (Official, 2026-05-03)
  • indications: This supplement provides for the addition of the indication for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabete… (Official, 2026-05-02)
  • indications: This supplement provides for the addition of the indication for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabete… (Official, 2026-04-29)
  • indications: This supplement provides for the addition of the indication for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabete… (Official, 2026-04-28)
  • indications: This supplement provides for the addition of the indication for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabete… (Official, 2026-04-27)
  • indications: This supplement provides for the addition of the indication for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabete… (Official, 2026-04-26)
  • indications: This supplement provides for the addition of the indication for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabete… (Official, 2026-04-25)
  • indications: This supplement provides for the addition of the indication for the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabete… (Official, 2026-04-22)
  • side_effects: Top reported reactions (openFDA): INEFFECTIVE, GLYCEMIC CONTROL, Lack of efficacy - NOS, Hypoglycaemia, INEFFECTIVE, LOSS OF EFFECT, Wrong technique in drug us… (Official, 2026-04-22)
  • side_effects: Top reported reactions (openFDA): INEFFECTIVE, GLYCEMIC CONTROL, Lack of efficacy - NOS, Hypoglycaemia, INEFFECTIVE, LOSS OF EFFECT, Wrong technique in drug us… (Official, 2026-04-22)
  • side_effects: Top reported reactions (openFDA): INEFFECTIVE, GLYCEMIC CONTROL, Lack of efficacy - NOS, Hypoglycaemia, INEFFECTIVE, LOSS OF EFFECT, Wrong technique in drug us… (Official, 2026-02-12)
  • usage: For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in cats with diabetes mellitus. For the reduction of hyperglycemia and hyperglyc… (Official, 2026-04-22)
Recent Revisions
  • side_effects updated 2026-04-22 10:13 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-22 10:13 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-22 10:13 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-15 10:04 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
ProZinc®
RX
Insulin
Liquid (Suspension) Subcutaneous
Boehringer Ingelheim Animal Health USA, Inc. NADA 141-297 Approved Nov 13, 2023

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each mL contains 40 international units (IU) insulin.
Cats
Indication
For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in cats with diabetes mellitus.
Dosage
The initial recommended dose is 0.1 to 0.3 IU insulin/pound of body weight (0.2 to 0.7 IU/kg) every 12 hours. The dose should be given concurrently with or right after a meal.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use of a syringe other than a U-40 syringe will result in incorrect dosing. For subcutaneous injection in cats only.
Dogs
Indication

For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabetes mellitus.

Dosage

Starting dose: The recommended starting dose for ProZinc® is 0.2-0.5 IU insulin/pound of body weight (0.5-1.0 IU/kg) once daily. The recommended starting dose for naïve dogs is the lower end of the dose range. The recommended starting dose for dogs with poorly controlled diabetes mellitus and transitioning from another insulin product is the mid to higher end of the dose range based on the veterinarian’s experience with the dog’s medical history and previous insulin dose. When transitioning from another insulin, the dog’s blood glucose and general condition should be closely monitored. When transitioning from another insulin, ProZinc® should be started once daily regardless of the frequency of prior insulin use.

The dose should be given concurrently with or right after a meal. The veterinarian should re-evaluate the dog at appropriate intervals and adjust the dose and frequency based on both clinical signs and laboratory test results (the blood glucose curve values and shape, nadir, and fructosamine) until adequate glycemic control has been attained. In the effectiveness field study, glycemic control was considered adequate if the glucose nadir from a 9-hour blood glucose curve was between 80 and 125 mg/dL, the maximum blood glucose was lessThanEqualTo 300 mg/dL, and clinical signs of hyperglycemia such as polyuria, polydipsia, or weight loss were improved.

Changing to twice daily dosing: Twice daily dosing should be considered if the duration of insulin action is determined to be inadequate with once daily dosing. Use caution when adjusting from once daily to twice daily dosing because ProZinc® may have prolonged duration of action in some dogs. The veterinarian should closely monitor the duration of action using blood glucose curves to avoid the increased risk of hypoglycemia. If twice daily dosing is initiated, the two doses should each be approximately 25% less than the once daily dose required to attain an acceptable glucose nadir. For example, if a dog receiving 10 units of ProZinc® once daily has an acceptable nadir but inadequate duration of activity, the dose should be changed to 7 units twice daily (round down to the nearest whole unit).

Further adjustments in the dosage may be necessary with changes in the dog’s diet, body weight, or concomitant medication, or if the dog develops concurrent infection, inflammation, neoplasia, or an additional endocrine or other medical disorder.

Limitations

FDA page: Open in Animal Drugs @ FDA

Usage

For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in cats with diabetes mellitus. For the reduction of hyperglycemia and hyperglycemia-associated clinical signs in dogs with diabetes mellitus.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use of a syringe other than a U-40 syringe will result in incorrect dosing. For subcutaneous injection in cats only.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite (1) • Cat Diarrhea (1) • Cat Decreased appetite (1) • Cat Appetite disorder NOS (1) • Dog

Showing top 5 for Digestive.

Neurologic
Unsteady walking (1) • Dog

Showing top 5 for Neurologic.

Behavior
Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Other
Elevated creatinine (1) • Cat Elevated cholesterol (1) • Dog Elevated blood urea nitrogen (1) • Dog Elevated alanine aminotransferase (1) • Cat Dull (1) • Dog
Show more (21)
Distress (1) • Cat Digestive tract disorder NOS (1) • Cat Difficulty in micturition (1) • Cat Diabetic ketoacidosis (1) • Cat Diabetes (1) • Cat Dental disease (1) • Cat Dehydration (1) • Cat Decreased red blood cell count (1) • Cat Decreased haematocrit (1) • Cat Decreased body temperature (1) • Cat Death by euthanasia (1) • Cat Death (1) • Dog Cushings disease NOS (1) • Dog Constipation (1) • Cat Complication of diabetes (1) • Dog Color, Abnormal (1) • Cat Collapse NOS (1) • Dog Cold feeling to the touch (1) • Cat Arthritis (1) • Cat Anaemia NOS (1) • Cat Adrenal gland disorder NOS (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, ['Terrier - Silky', 'Dog (unknown)'], Male, 13.5 year, 6.078 kilogram • Drug: MSK, Injection, Subcutaneous • Reactions: Diarrhea, Polyuria, Hyperglycaemia, Elevated blood urea nitrogen, Hyperkalaemia… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-075121
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 13.50 Year
  • Weight: 6.078 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Injection
Reactions Reported:
Diarrhea Polyuria Hyperglycaemia Elevated blood urea nitrogen Hyperkalaemia Low sodium-potassium ratio
Outcomes: Outcome Unknown

Dog, Retriever - Labrador, Female, 5.1 year, 29.8 kilogram • Drug: MSK, Unassigned, Subcutaneous, Dose: 23 Other per animal, Frequency: 12 per hour • Reactions: Lack of efficacy - NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074486
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 5.10 Year
  • Weight: 29.800 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Unassigned
  • Dose: 23 Other per animal
  • Frequency: 12 per hour
Reactions Reported:
Lack of efficacy - NOS
Outcomes: Ongoing

Dog, Siberian Husky, Male, 11 year, 30.16 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Polyuria, Polydipsia, Skin discolouration NOS, Poor coat condition, Complication of diabetes… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074352
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 11.00 Year
  • Weight: 30.160 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Polyuria Polydipsia Skin discolouration NOS Poor coat condition Complication of diabetes Elevated thyroxine Elevated cholesterol Partial lack of efficacy Weight gain
Outcomes: Ongoing

Dog, ['Retriever - Labrador', 'Dog (unknown)'], Female, 11 year, 28.304 kilogram • Drug: MSK, Suspension, Unknown, Frequency: 12 per hour • Reactions: Death, Tiredness (lethargy), Vomiting • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-073880
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 28.304 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Suspension
  • Frequency: 12 per hour
Reactions Reported:
Death Tiredness (lethargy) Vomiting
Outcomes: Died

Dog, ['Poodle (unspecified)', 'Dog (unknown)'], Male, 12.2 year, 5.534 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Seizure NOS, Hyperglycaemia • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074515
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 12.20 Year
  • Weight: 5.534 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Seizure NOS Hyperglycaemia
Outcomes: Ongoing

Dog, Retriever - Labrador, Female, 14 year, 31.8 kilogram • Drug: MSK, Unknown, Frequency: 12 per hour • Reactions: Watery diarrhoea • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-073465
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 14.00 Year
  • Weight: 31.800 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Frequency: 12 per hour
Reactions Reported:
Watery diarrhoea
Outcomes: Outcome Unknown

Cat, Domestic Shorthair, Male, 15 year, 9.253 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Joint swelling, Pain NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-071549
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 15.00 Year
  • Weight: 9.253 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Joint swelling Pain NOS
Outcomes: Ongoing

Cat, Domestic Shorthair, Male, 16 year, 5.761 kilogram • Drug: MSK, Unassigned, Unknown, Dose: 2 Other per animal, Frequency: 12 per hour • Reactions: Diarrhea, Gait abnormality, Vocalisation • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-071470
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 16.00 Year
  • Weight: 5.761 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
  • Dose: 2 Other per animal
  • Frequency: 12 per hour
Reactions Reported:
Diarrhea Gait abnormality Vocalisation
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.